statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer PR Newswire PHILADELPHIA, May 2, 2024...

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Carisma Therapeutics to Present New Data at the American Society of Gene and Cell...

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Carisma Therapeutics to Present at Upcoming Conferences Carisma Therapeutics to Present at Upcoming Conferences PR Newswire PHILADELPHIA, April 3, 2024 PHILADELPHIA, April 3, 2024 /PRNewswire...

Carisma Therapeutics to Present at Upcoming Conferences

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Carisma Therapeutics reports Q2 EPS (52c), consensus (55c)

Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year...

Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Carisma Therapeutics Announces Changes to its Board of Directors Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, April 1, 2024 Appointment of JohnHohneker...

Carisma Therapeutics Announces Changes to its Board of Directors

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
CARM stock results show that CARISMA Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth...

CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q4 2023

Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting Carisma Announces Upcoming Presentations at the American Association for Cancer Research...

Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference PR Newswire PHILADELPHIA...

Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM  Get Free Report) have received an average recommendation of Buy from the five research firms that are currently covering the...

Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of "Buy" by Brokerages

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

Volume	61,910.00
52-Wk High	$9.77
52-Wk Low	$1.53

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.43	--	--	N/A
Q4'23	-$0.55	-$0.52	5.88%	BEAT
Q3'23	-$0.57	-$0.53	7.02%	BEAT
Q2'23	-$0.60	-$0.49	17.88%	BEAT
Q1'23	-$0.89	-$1.93	-116.85%	MISSED

CARM Carisma Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals